Literature DB >> 19680647

Skeletal metastases: what is the future role for nuclear medicine?

Gary J R Cook.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19680647     DOI： 10.1007/s00259-009-1240-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  37 in total

1.  Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer.

Authors:  H Schirrmeister; G Glatting; J Hetzel; K Nüssle; C Arslandemir; A K Buck; K Dziuk; A Gabelmann; S N Reske; M Hetzel
Journal:  J Nucl Med       Date:  2001-12       Impact factor: 10.057

2.  SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients.

Authors:  Wolfgang Römer; Anton Nömayr; Michael Uder; Werner Bautz; Torsten Kuwert
Journal:  J Nucl Med       Date:  2006-07       Impact factor: 10.057

3.  Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy.

Authors:  M Ohta; Y Tokuda; Y Suzuki; M Kubota; H Makuuchi; T Tajima; S Nasu; Y Suzuki; S Yasuda; A Shohtsu
Journal:  Nucl Med Commun       Date:  2001-08       Impact factor: 1.690

Review 4.  Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate.

Authors:  G M Blake; S J Park-Holohan; G J Cook; I Fogelman
Journal:  Semin Nucl Med       Date:  2001-01       Impact factor: 4.446

5.  MRI and (18)FDG-PET in the assessment of bone marrow infiltration of the spine in cancer patients.

Authors:  Nadir Alexander Ghanem; Gregor Pache; Christian Lohrmann; Ingo Brink; Thorsten Bley; Elmar Kotter; Thomas Kelly; Mathias Langer
Journal:  Eur Spine J       Date:  2007-04-03       Impact factor: 3.134

6.  [18F]fluorodeoxyglucose positron emission tomography is more sensitive than skeletal scintigraphy for detecting bone metastasis in endemic nasopharyngeal carcinoma at initial staging.

Authors:  Feng-Yuan Liu; Joseph T Chang; Hung-Ming Wang; Chun-Ta Liao; Chung-Jan Kang; Shu-Hang Ng; Shu-Kung Ng; Sheng-Chieh Chan; Tzu-Chen Yen
Journal:  J Clin Oncol       Date:  2006-02-01       Impact factor: 44.544

7.  F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management.

Authors:  Martin Hetzel; Coskun Arslandemir; Hans-Helmut König; Andreas K Buck; Karin Nüssle; Gerhard Glatting; Andreas Gabelmann; Jürgen Hetzel; Vinzenz Hombach; Holger Schirrmeister
Journal:  J Bone Miner Res       Date:  2003-12       Impact factor: 6.741

8.  Comparison of whole-body MRI and bone scintigraphy in the detection of bone metastases in renal cancer.

Authors:  S A Sohaib; G Cook; S D Allen; M Hughes; T Eisen; M Gore
Journal:  Br J Radiol       Date:  2009-02-16       Impact factor: 3.039

9.  Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer.

Authors:  Holger Schirrmeister; Coskun Arslandemir; Gerhard Glatting; Regine Mayer-Steinacker; Martin Bommer; Karsten Dreinhöfer; Andreas Buck; Martin Hetzel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-28       Impact factor: 9.236

10.  Localization of technetium-99m methylene diphosphonate in bone using microautoradiography.

Authors:  T A Einhorn; V J Vigorita; A Aaron
Journal:  J Orthop Res       Date:  1986       Impact factor: 3.494
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.